Elicio Therapeutics (ELTX) Capital Expenditures (2020 - 2025)
Elicio Therapeutics posted quarterly Capital Expenditures of $16000.0 for Q4 2025, down 64.44% year-on-year from $45000.0 in Q4 2024, and down 64.44% on a QoQ basis from $45000.0 in Q4 2024.
Elicio Therapeutics (ELTX) has 6 years of Capital Expenditures data on file, last reported at $16000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 64.44% year-over-year to $16000.0; the trailing twelve-month figure through Dec 2025 stood at $61000.0 (down 29.89% YoY), and the FY2025 full-year result was $16000.0, down 81.61% from the prior year.
- Capital Expenditures for Q4 2025 stood at $16000.0, down from $45000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $559000.0 in Q2 2022 and bottomed at -$342000.0 in Q4 2021.
- The 5-year median for Capital Expenditures is $43500.0 (2023), against an average of $68916.7.
- Peak annual rise in Capital Expenditures reached 2340.0% in 2021, while the deepest fall reached 8650.0% in 2021.
- A 5-year view of Capital Expenditures shows it stood at -$342000.0 in 2021, then surged by 127.78% to $95000.0 in 2022, then slumped by 52.63% to $45000.0 in 2023, then changed by 0.0% to $45000.0 in 2024, then sank by 64.44% to $16000.0 in 2025.
- The last three Capital Expenditures figures came in at $16000.0 (Q4 2025), $45000.0 (Q4 2024), and $42000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 17,000.00 |
| Mar 31, 2023 | 17,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Jun 30, 2022 | 559,000.00 |
| Jun 30, 2022 | 559,000.00 |
| Dec 31, 2021 | -342,000.00 |
| Dec 31, 2021 | -342,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 244,000.00 |
| Jun 30, 2021 | 244,000.00 |
| Mar 31, 2021 | 41,000.00 |
| Mar 31, 2021 | 41,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Sep 30, 2020 | -30,000.00 |
| Sep 30, 2020 | -30,000.00 |
| Jun 30, 2020 | 10,000.00 |
| Jun 30, 2020 | 10,000.00 |
| Mar 31, 2020 | 20,000.00 |
| Mar 31, 2020 | 20,000.00 |